Abstract:A tailor‐made photosensitizer based on boron dipyrromethene conjugated with a galactose moiety through a self‐immolative linker has been designed and synthesized. It exhibits a selective response toward the senescence‐associated β‐galactosidase, rendering it an efficient theranostic behavior for detection and photodynamic elimination of senescent cells in vitro and in vivo. Senescence is a cellular response having physiological and reparative functions to preserve tissue homeostasis and suppress tumor growth. However, the accumulation of senescent cells would cause deleterious effects that lead to age‐related dysfunctions and cancer progression. Hence, selective detection and elimination of senescent cells are crucial yet remain a challenge. A β‐galactosidase (β‐gal)‐activated boron dipyrromethene (BODIPY)‐based photosensitizer (compound 1) is reported here that can selectively detect and eradicate senescent cells. It contains a galactose moiety connected to a pyridinium BODIPY via a self‐immolative nitrophenylene linker, of which the photoactivity is effectively quenched. Upon interactions with the senescence‐associated β‐gal, it undergoes enzymatic hydrolysis followed by self‐immolation, leading to the release of an activated BODIPY moiety by which the fluorescence emission and singlet oxygen generation are restored. The ability of 1 to detect and eliminate senescent cells is demonstrated in vitro and in vivo, using SK‐Mel‐103 tumor‐bearing mice treated with senescence‐inducing therapy. The results demonstrate that 1 can be selectively activated in senescent cells to trigger a robust senolytic effect upon irradiation. This study breaks new ground in the design and application of new senolytic agents based on photodynamic therapy.

A senolytic strategy integrating multiple technologies delays aging

Photoactivatable senolysis with single-cell resolution delays aging

Targeted clearance of senescent cells using an antibody-drug conjugate against a specific membrane marker

Senolytic Therapy Enabled by Senescent Cell‐Sensitive Biomimetic Melanin Nano‐senolytics

Senolysis Enabled by Senescent Cell‐Sensitive Bioorthogonal Tetrazine Ligation

Senolytic Prodrugs: A Promising Approach to Enhancing Senescence-Targeting Intervention

Illuminating anti-ageing

Advances in Nanotherapy for Targeting Senescent Cells

Spatially Confined Intervention of Cellular Senescence by a Lysosomal Metabolism Targeting Molecular Prodrug for Broad-Spectrum Senotherapy

Development of novel flavonoid senolytics through phenotypic drug screening and drug design

Recent Advances in Strategies for Imaging Detection and Intervention of Cellular Senescence

Engineering Hierarchical Recognition-Mediated Senolytics for Reliable Regulation of Cellular Senescence and Anti-Atherosclerosis Therapy

Repurposing the plant-derived compound apigenin for senomorphic effect in antiaging pipelines

Targeting Cellular Senescence in Aging and Age-Related Diseases: Challenges, Considerations, and the Emerging Role of Senolytic and Senomorphic Therapies

Inhibitor PF-04691502 works as a senolytic to regulate cellular senescence

Targeted Delivery Strategy: A Beneficial Partner for Emerging Senotherapy

β‐Galactosidase‐Triggered Photodynamic Elimination of Senescent Cells with a Boron Dipyrromethene‐Based Photosensitizer

Targeting Senescent Cells for a Healthier Longevity: the Roadmap for an Era of Global Aging

Targeting cellular senescence with senotherapeutics: senolytics and senomorphics

Detection and Elimination of Senescent Cells with a Self-Assembled Senescence-Associated β-Galactosidase-Activatable Nanophotosensitizer

Elimination of senescent cells by β-galactosidase-targeted prodrug attenuates inflammation and restores physical function in aged mice